Common Causes For Essential Amino Acids Deficiency

If you want to ensure that you have all the essential amino acids that your body needs, buying amino acids online is the best and easiest way to avoid developing a deficiency. You can purchase amino acid supplements from Sunshine Biopharma Nutrition and get everything your body needs right now.

However, if you are suffering from an amino acids deficiency, here are some common reasons why this could be happening to you.

You’re Getting Older

Ageing causes acid levels in the stomach to decrease by as much as 40% from your teenage years to your thirties and to almost half again by the time you’re 70. This means that your digestive abilities decrease significantly with age. Because of your decreased digestive ability, your body won’t be able to digest proteins nearly as well as it used to. As a result, you might develop an amino acid deficiency and thus need to take a supplement.

You’re Not Eating Enough Protein

Amino acids primarily come from protein-rich foods. The best source of amino acids is animal-based foods such as various kinds of meat, including beef, pork, turkey, chicken and fish, as well as eggs, milk, cheese, yogurt and other dairy products. These are all high in protein and provide significant amino acids.

If, for whatever reason, you are not consuming enough protein-rich foods, you will not get enough amino acids into your body through your diet. This is a common problem with those who follow a vegan or vegetarian lifestyle.

However, they are a significant amount of plant-based proteins from which one could derive amino acids, such as beans, chia seeds and soy ‒ although these are not as rich or varied as their animal-based counterparts.

It is generally recommended that those who follow a vegan or vegetarian lifestyle take an amino acid supplement to ensure they get everything they need.

You Have Poor Digestion

In some cases, physical disabilities might inhibit the efficient breakdown of proteins and prevent the body from adequately synthesizing amino acids from one’s diet. A supplement might be in order if a person suffers from some kind of inherited biochemical ailment or anomaly that inhibits their ability to break proteins down.

In some cases, a lack of hydrochloric acid ‒ a powerful and necessary gastric acid ‒ can prevent one from successfully digesting proteins. There are various treatments for this kind of thing. However, it is generally recommended that an amino acids supplement be incorporated into this treatment.

If you suffer from a deficiency, buy amino acids today. Order your supplements now at Sunshine Biopharma Nutrition and look after your health!

What Happens When You Have An Amino Acids Deficiency?

It is very difficult for one to get all nine essential amino acids through diet alone nowadays. This is because we all live very fast-paced lives, often eating poorly. Therefore, we seldom get everything we need through nutrition alone. Processed foods and other unhealthy eating habits can quickly lead to deficiencies, severely impacting one’s life.

Therefore, it is highly recommended that you consider taking a good quality essential amino acids supplement to ensure that you’re not missing anything.

Let us look at some of the effects an amino acid deficiency could have on the body and mind.

The Physical Effects 

The importance of protein in your nutritional intake is critical. It gives structure to your tissue and the cells that make it, supporting the strength and reliability of your organs and your muscles.

When these parts of your body don’t function as well as they should, you might suffer from immunity problems, hormone production issues, and other intercellular communication inefficiencies.

When your body does not get the essential amino acids from your diet that it needs, it will start to seek them out elsewhere in your body. This leads to the breakdown of muscle tissue and the depletion of other proteins as your body attempts to compensate, resulting in symptoms such as weakness, fatigue, decreased hair and skin quality, a compromised immune response and a loss of musculature.

The Mental Effects

Amino acids are also critical for one’s mental and psychological stability. It is well known that hormonal fluctuations can affect one’s psychological state by impacting emotions. Fatigue can also significantly contribute to decreased mental ability and one’s ability to concentrate and remain focused.

When one is tired, brain fog commonly occurs, which can contribute to stress and anxiety. When these things begin to affect one’s ability to perform at one’s job, it is not uncommon to result in stress and even depression. When all of these factors compound on top of one another, the effects of amino acid deficiency on one’s mental and psychological state can be quite significant and thus should not be underestimated.

At Sunshine Biopharma Nutrition, we have all the best supplements your body needs. Order your essential amino acids supplement today and give your body a fighting chance.

What Nutritional Supplements Can Do For You

Never before in history has it been this easy to remain in good health and receive the best nutrition that money can buy.

While our diets can be more varied than ever before, thanks to the globalization of the food industry, and the ability to order a range of products that you would not usually be able to get in your own country, you can have pretty much whatever you want, whenever you want, if you can afford it.

However, this does not necessarily mean that it is easy to acquire all the nutrients your body needs through your daily diet because of our fast-paced lifestyles. In addition, we are forced to eat processed foods more often out of convenience, which does not always have the range of nutrients you would ideally want or need. Several reasons could exist for this can be expensive and time-consuming to cook the foot and find it. Grocery shopping can be a tedious task. Add to that time taken to prepare the food.

Supplementing Your Diet

This often results in people simply going for the simplest and quickest solution, sadly resulting in substandard nutrition. However, thanks to emerging biopharma companies such as Sunshine Biopharma Nutrition, you can supplement this diet with nutritional supplements.

When consumed, these supplements will ensure that you will never miss out on what your body needs, providing a healthier and more productive environment.

How Do Supplements Help Me? 

If you are involved in athleticism as a trainer or bodybuilder, or perhaps you are engaged in a sport where your performance needs to be at its peak, nutritional supplements are essential.

When competing in strenuous physical activities, not only could a lack of proper nutrition result in failing to succeed in those endeavours, but you could also run the risk of injuring yourself if your body is not properly looked after.

If you operate in a high-stress work environment, where your mind is working overtime, you are under a lot of pressure; you have to think fast and act at high-efficiency levels, then you cannot afford to have your body be in poor condition owing to bad nutrition.

Taking a well-rounded set of nutritional supplements can significantly improve your ability to function and do your job without running the risk of failing at your tasks and hitting burnout, which can have devastating effects on your mental well-being and career.

To order your nutritional supplements online from one of the most exciting emerging biopharma nutrition companies on the market, contact Sunshine Biopharma Nutrition today and let us help you get your body in tip-top shape that can take on the world.

What Is So Important About Amino Acids?

Amino acids are the foundational building blocks of proteins, and proteins are the building blocks of life. Therefore, your body must get the amino acids it needs to maintain its protein structures and health.

Of the many different amino acids that exist, nine are deemed essential. This means that these nine amino acids cannot be formulated inside your body without the assistance of outside inputs. These amino acids need to be consumed through the food you eat and, therefore, are highly dependent on nutrition.

However, it is difficult to ensure that all nine essential amino acids are found in your diet every day, so deficiencies in several of these amino acids are relatively common.

What Do Essential Amino Acids Do For You?

Amino acids are responsible for causing a variety of different chemical reactions in the body. They are also responsible for transporting nutrients and helping you stay healthy and avoid illness.

Amino acids help you grow and maintain muscles and aid digestion and various other vital bodily functions. In addition, they improve sleep, reduce fatigue, provide energy and help you manage weight.

What Does A Deficiency Of Essential Amino Acids Do To You?

One of the significant problems caused by an amino acid deficiency is a decreased immunity to disease and illness. It can also lead to you having digestive problems and can sometimes cause depression.

Fertility issues can also be associated with a deficiency in essential amino acids, and so an amino acid supplement regime is a standard treatment for couples trying to fall pregnant.

Sometimes, if you experience brain fog, fatigue or lower mental alertness, simply boosting your amino acid intake can make a massive difference.

In some cases, a severe deficiency in amino acids can result in slowed or delayed growth among children, leading to lifelong health and psychological issues.

Many other health issues can be attributed to an amino acid deficiency. Therefore, you must always get all nine essential amino acids in your diet.

How Can I Make Sure I’m Getting Enough Essential Amino Acids?

Your body needs 20 amino acids in total. Eleven of these can be manufactured by the body without any outside assistance. However, the 9 remaining essential amino acids need to be absorbed from outside to ensure you receive all the amino acids you need.

We recommend that you take an amino acid supplement, which covers all of your bases and ensures that you are not deficient in any of the nine essential amino acids.

Order your 9 essential amino acids supplement today from Sunshine Biopharma Nutrition and stay healthy!

Why Biopharma Is Changing The Face Of Medicine Today

As one of the most exciting emerging biopharma companies in Canada, we at Sunshine Biopharma Nutrition are at the forefront of the biopharma revolution.

Biopharma is all about using advanced biotechnology to extract living organisms and organic components ‒ such as sugars, proteins, amino acids, nucleic acids and more ‒ from biological sources, such as people, animals or plants, to synthesize medicines and supplements. The products manufactured through biopharma are identical to naturally occurring products found in nature, which is why they are so effective.

Medicines

Biopharmaceuticals are changing the way we understand and use medicine. Conditions such as cardiovascular disease, cancer, diabetes and even HIV are being treated with biopharmaceuticals with great success and minimal to no side effects.

Biopharma is not made using an array of potentially harmful chemicals the way normal pharmaceuticals are made. Regular pharmaceuticals can have devastating side effects on the human body, especially if used for extended periods.

Moreover, regular pharmaceuticals can be extremely expensive and, in many cases, dependencies tend to form, leading to problems later on.

Biopharma is highly effective at preventing health problems from occurring in the first place, while also being very useful in treating and managing various conditions.

Supplements

Aside from an array of medicines, biopharma is responsible for providing numerous nutritional supplements, from protein powders to amino acid supplements and everything in between.

These natural, non-chemical supplements are highly effective at preventing disease, as well as treating a variety of medical issues. These issues can range from treating mild fatigue or a headache to treating full-blown cancer.

By taking the right supplements in accordance with a healthy lifestyle consisting of exercise and smart food choices, your health is guaranteed to improve.

Supplements can also help you improve your performance. If you’re an athlete and need your body to be in peak physical condition, or you’re trying to build muscle, or perhaps you just want to be able to think more clearly because finals are coming up, biopharmaceutical nutritional supplements can make a huge difference.

If you’re looking to improve your health, contact Sunshine Biopharma Nutrition, one of the most promising emerging biopharma companies, and let us advise you on the best supplements to suit your lifestyle and health goals.

Sunshine Biopharma’s Newly Designed mRNA Molecules Prove Effective Against Multidrug Resistant Cancer Cells

A Potential Multi-Billion Dollar Global Market Opportunity for Cancer Treatments

Montreal, Quebec, Canada – (GLOBE NEWSWIRE) – Sunshine Biopharma, Inc. (NASDAQ: “SBFM” and “SBFMW”), a biopharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs, today announced that two of its newly designed mRNA molecules are effective at destroying cancer cells grown in culture.

The cytotoxicity tests were performed on a variety of cancer cells including multidrug resistant breast cancer cells (MCF-7/MDR), ovarian adenocarcinoma cells (OVCAR-3), and pancreatic cancer cells (SUIT-2). Toxicity studies using non-transformed (normal) human cells (HMEC cells) showed that these mRNA molecules had little or no cytotoxic effects. These new mRNA molecules are readily adaptable for delivery into patients using the mRNA vaccine technology. The Company anticipates filing a patent application in connection with these results soon.

“We are delighted by these findings in connection with our ongoing mRNA-as-therapeutic-agents research,” said Dr. Steve Slilaty, CEO of Sunshine Biopharma. “The potential use of mRNA to treat cancer opens the door to many possibilities for patients including convenience, reduced toxicity and enhanced efficacy,“ he added.

About Sunshine Biopharma

Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) is the causative agent of the ongoing COVID-19 pandemic that has claimed the lives of over 6.1 million people worldwide since it first appeared in December 2019. Sunshine Biopharma is working on the development of a treatment for COVID-19 and has completed the synthesis of four potential inhibitors of PLpro and subsequently identified a lead compound, SBFM-PL4. In addition, the Company recently expanded its research efforts into finding other PLpro inhibitors by entering into a collaboration agreement with the University of Arizona. The collaboration is focused on determining the in vivo safety, pharmacokinetics, and dose selection properties of three University of Arizona owned PLpro inhibitors, followed by efficacy testing in mice infected with SARS-CoV-2. The Company

holds the first option to negotiate for a commercial, royalty-bearing license for all intellectual property developed by University of Arizona under the research project.

In addition to working on the development of a treatment for COVID-19, Sunshine Biopharma is engaged in the development of Adva-27a, a unique anticancer compound. Tests conducted to date have demonstrated the effectiveness of Adva-27a at destroying Multidrug Resistant Cancer Cells, including Pancreatic Cancer cells, Small-Cell Lung Cancer cells, Breast Cancer cells, and Uterine Sarcoma cells. Clinical trials for Pancreatic Cancer indication are planned to be conducted at McGill University’s Jewish General Hospital in Montreal, Canada. Sunshine Biopharma is owner of all patents and intellectual property pertaining to Adva-27a.

Cautionary Note Regarding Forward Looking Statements

This press release and statements of the Company’s management made in connection therewith contain “forward-looking statements” (as defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended) concerning future events. Words such as “may”, “could”, “expects”, “projects,” “intends”, “plans”, “believes”, “predicts”, “anticipates”, “hopes”, “estimates” and variations of such words and similar expressions are intended to identify forward-looking statements. These statements appear in a number of places in this release and include all statements that are not statements of historical fact. These statements involve known and unknown risks and are based upon several assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond the Company’s control. Actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, the risk factors described in the Company’s filings with the SEC. The Company’s SEC filings can be obtained free of charge on the SEC’s website at www.sec.gov. Except to the extent required by law, Sunshine Biopharma, Inc. (the “Company”) expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company’s expectations with respect thereto or any change in events, conditions, or circumstances on which any statement is based.

For Additional Information:

Sunshine Biopharma Media Contacts: TraDigital IR
Direct Line: 917-633-8980 [email protected]

Sunshine Biopharma Inc. Contacts: Camille Sebaaly, CFO
Direct Line: 514-814-0464 [email protected] www.sunshinebiopharma.com

Sunshine Biopharma, Inc. Announces Closing of $8.0 Million Private Placement Priced At-the-Market

 

MONTREAL, Canada, March 14, 2022 (GLOBE NEWSWIRE) — Sunshine Biopharma, Inc.
(NASDAQ: “SBFM” and “SBFMW”) (the “Company” or “Sunshine Biopharma”), a pharmaceutical
company focused on the research, development and commercialization of oncology and antiviral
drugs, today closed its previously announced private placement pursuant to a securities purchase
agreement entered into on March 10, 2022 with certain institutional and accredited investors.

In connection with the private placement, the Company issued (i) 2,301,353 shares of its Common
Stock together with investor warrants (“Investor Warrants”) to purchase up to 2,301,353 shares of
Common Stock, and (ii) 1,302,251 pre-funded warrants (“Pre-Funded Warrants”) with each PreFunded Warrant exercisable for one share of Common Stock, together with Investor Warrants to
purchase up to 1,302,251 shares of Common Stock. Each share of Common Stock and accompanying
Investor Warrant were sold together at a combined offering price of $2.22, and each Pre-Funded
Warrant and accompanying Investor Warrant were sold together at a combined offering price of
$2.219, priced at-the-market under Nasdaq rules.

The Pre-Funded Warrants are immediately exercisable, at a nominal exercise price of $0.001, and may
be exercised at any time until all of the Pre-Funded Warrants are exercised in full. The Investor
Warrants have an exercise price of $2.22 per share (subject to adjustment as set forth in the warrant),
are exercisable upon issuance and will expire five years from the date of issuance.
The Company received gross proceeds of approximately $8 million before deducting transaction
related expenses payable by the Company.


Aegis Capital Corp. acted as the Exclusive Placement Agent in connection with the offering.
Additional details regarding the offering will be available in a Form 8-K to be filed by the Company
with the U.S. Securities and Exchange Commission (the “SEC”).


The shares of common stock and warrants described above have not been registered under the
Securities Act of 1933, as amended, and may not be offered or sold in the United States absent
registration with the Securities and Exchange Commission (SEC) or an applicable exemption from
such registration requirements. The securities were offered only to accredited investors. Pursuant to a
registration rights agreement with the investors, the Company has agreed to file one or more
registration statements with the SEC covering the resale of the shares of common stock and the shares
issuable upon exercise of the warrants.


This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall
there be any sale of these securities in any state or other jurisdiction in which such an offer, solicitation
or sale would be unlawful prior to registration or qualification under the securities laws of any such
state or other jurisdiction.


About Sunshine Biopharma
Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) is the causative agent of the
ongoing COVID-19 pandemic that has claimed the lives of over 6 million people worldwide since it
first appeared in December 2019. Sunshine Biopharma is working on the development of a treatment
for COVID-19 and has completed the synthesis of four potential inhibitors of PLpro and
subsequently identified a lead compound, SBFM-PL4. The Company is currently advancing the
development of SBFM-PL4 in collaboration with the University of Georgia, College of Pharmacy. In
addition, the Company recently signed a collaboration with the University of Arizona aimed at
assessing the efficacy of three University of Arizona PLpro inhibitors in mice.
In addition, to working on the development of a treatment for COVID-19, Sunshine Biopharma is
engaged in the development Adva-27a, a unique anticancer compound. Tests conducted to date have
demonstrated the effectiveness of Adva-27a at destroying Multidrug Resistant Cancer Cells, including
Pancreatic Cancer cells, Small-Cell Lung Cancer cells, Breast Cancer cells, and Uterine Sarcoma cells.
Clinical trials for Pancreatic Cancer indication are planned to be conducted at McGill University’s
Jewish General Hospital in Montreal, Canada. Sunshine Biopharma is owner of all patents and
intellectual property pertaining to Adva-27a.


Cautionary Note Regarding Forward Looking Statements
This press release and statements of the Company’s management made in connection therewith
contain “forward-looking statements” (as defined in Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as amended) concerning future
events. Words such as “may”, “could”, “expects”, “projects,” “intends”, “plans”, “believes”, “predicts”,
“anticipates”, “hopes”, “estimates” and variations of such words and similar expressions are intended
to identify forward-looking statements. These statements involve known and unknown risks and are
based upon several assumptions and estimates, which are inherently subject to significant uncertainties
and contingencies, many of which are beyond the Company’s control. Actual results may differ
materially from those expressed or implied by such forward-looking statements. Factors that could
cause actual results to differ materially include, but are not limited to, the risk factors described in the
Company’s filings with the SEC. The Company’s SEC filings can be obtained free of charge on the
SEC’s website at www.sec.gov. Except to the extent required by law, the Company expressly disclaims
any obligations or undertaking to release publicly any updates or revisions to any forward-looking
statements contained herein to reflect any change in the Company’s expectations with respect thereto
or any change in events, conditions, or circumstances on which any statement is based.


For Additional Information:
Sunshine Biopharma Media Contacts:
TraDigital IR
Direct Line: 917-633-8980
[email protected]


Sunshine Biopharma Inc. Contacts:
Camille Sebaaly, CFO
Direct Line: 514-814-0464
[email protected]
www.sunshinebiopharma.com

Sunshine Biopharma, Inc. Announces Pricing of $8.0 Million Private Placement Priced At-the-Market

 

 MONTREAL, Canada, March 10, 2022 (GLOBE NEWSWIRE) — Sunshine Biopharma, Inc.
(NASDAQ: “SBFM” and “SBFMW”) (the “Company” or “Sunshine Biopharma”), a pharmaceutical
company focused on the research, development and commercialization of oncology and antiviral
drugs, today announced that it entered into a securities purchase agreement with certain institutional
and accredited investors for aggregate gross proceeds of approximately $8.0 million, before deducting
fees to the placement agent and other offering expenses payable by the Company.


In connection with the offering, the Company will issue 3,603,604 units at a purchase price of $2.22
per unit, priced at-the-market under Nasdaq rules. Each unit consists of 1 share of common stock or
common stock equivalent, and 1 non-tradable warrant, to purchase 1 share of common stock (for a
total of 3,603,604 shares underlying the warrants). No actual units will be issued in the offering.
The warrants each have an exercise price of $2.22, subject to adjustments therein. The warrant has a
term equal to five years from the issuance date.
The offering is expected to close on or about March 14, 2022, subject to the satisfaction of customary
closing conditions.


Aegis Capital Corp. is acting as the Exclusive Placement Agent in connection with the
offering.
Additional details regarding the offering will be available in a Form 8-K to be filed by the Company
with the U.S. Securities and Exchange Commission (the “SEC”).
The shares of common stock and warrants described above have not been registered under the
Securities Act of 1933, as amended, and may not be offered or sold in the United States absent
registration with the Securities and Exchange Commission (SEC) or an applicable exemption from
such registration requirements. The securities were offered only to accredited investors. Pursuant to a
registration rights agreement with the investors, the Company has agreed to file one or more
registration statements with the SEC covering the resale of the shares of common stock and the shares
issuable upon exercise of the warrants.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the
securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in
which such offer, solicitation or sale would be unlawful prior to registration or qualification under the
securities laws of any such state or jurisdiction.


About Sunshine Biopharma
Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) is the causative agent of the
ongoing COVID-19 pandemic that has claimed the lives of over 6 million people worldwide since it
first appeared in December 2019. Sunshine Biopharma is working on the development of a treatment
for COVID-19 and has completed the synthesis of four potential inhibitors of PLpro and
subsequently identified a lead compound, SBFM-PL4. The Company is currently advancing the

development of SBFM-PL4 in collaboration with the University of Georgia, College of Pharmacy. In
addition, the Company recently signed a collaboration with the University of Arizona aimed at
assessing the efficacy of three University of Arizona PLpro inhibitors in mice.
In addition, to working on the development of a treatment for COVID-19, Sunshine Biopharma is
engaged in the development Adva-27a, a unique anticancer compound. Tests conducted to date have
demonstrated the effectiveness of Adva-27a at destroying Multidrug Resistant Cancer Cells, including
Pancreatic Cancer cells, Small-Cell Lung Cancer cells, Breast Cancer cells, and Uterine Sarcoma cells.
Clinical trials for Pancreatic Cancer indication are planned to be conducted at McGill University’s
Jewish General Hospital in Montreal, Canada. Sunshine Biopharma is owner of all patents and
intellectual property pertaining to Adva-27a.
In addition, to working on the development of a treatment for COVID-19, Sunshine Biopharma is
engaged in the development Adva-27a, a unique anticancer compound. Tests conducted to date have
demonstrated the effectiveness of Adva-27a at destroying Multidrug Resistant Cancer Cells, including
Pancreatic Cancer cells, Small-Cell Lung Cancer cells, Breast Cancer cells, and Uterine Sarcoma cells.
Clinical trials for Pancreatic Cancer indication are planned to be conducted at McGill University’s
Jewish General Hospital in Montreal, Canada. Sunshine Biopharma is owner of all patents and
intellectual property pertaining to Adva-27a.


Cautionary Note Regarding Forward Looking Statements
This press release and statements of the Company’s management made in connection therewith
contain “forward-looking statements” (as defined in Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as amended) concerning future
events, particularly with respect to the offering described herein. Words such as “may”, “could”,
“expects”, “projects,” “intends”, “plans”, “believes”, “predicts”, “anticipates”, “hopes”, “estimates”
and variations of such words and similar expressions are intended to identify forward-looking
statements. These statements involve known and unknown risks and are based upon several
assumptions and estimates, which are inherently subject to significant uncertainties and contingencies,
many of which are beyond the Company’s control. Actual results (including the anticipated benefits
of the offering described herein) may differ materially from those expressed or implied by such
forward-looking statements. Factors that could cause actual results to differ materially include, but are
not limited to, the risk factors described in the Company’s filings with the SEC. The Company’s SEC
filings can be obtained free of charge on the SEC’s website at www.sec.gov. Except to the extent
required by law, the Company expressly disclaims any obligations or undertaking to release publicly
any updates or revisions to any forward-looking statements contained herein to reflect any change in
the Company’s expectations with respect thereto or any change in events, conditions, or circumstances
on which any statement is based.

Related Tag: Pharmaceutical Development Company 


For Additional Information:
Sunshine Biopharma Media Contacts:

TraDigital IR
Direct Line: 917-633-8980
[email protected]


Sunshine Biopharma Inc. Contacts:
Camille Sebaaly, CFO
Direct Line: 514-814-0464
[email protected]
www.sunshinebiopharma.com

SUNSHINE BIOPHARMA EXPANDS ANTI-CORONAVIRUS DRUG DEVELOPMENT PROGRAM BY SIGNING A COLLABORATION AGREEMENT WITH THE UNIVERSITY OF ARIZONA

For Immediate Release February 25, 2022

Montreal, Canada – (GLOBE NEWSWIRE) – Sunshine Biopharma Inc. (NASDAQ: “SBFM” and
SBFMW) (the “Company” or “Sunshine Biopharma”), a pharmaceutical company focused on the
research, development and commercialization of oncology and antiviral drugs today announced
that it has entered into an agreement with the University of Arizona for the purposes of advancing
the development of novel PLpro inhibitors discovered by the University of Arizona and the University of
Illinois Chicago researchers. The development of the Company’s lead PLpro inhibitor, SBFMPL4,
is currently continuing at the University of Georgia. At the University of Arizona, the research
effort will focus on determining the in vivo safety, pharmacokinetics, and dose selection properties
of 3 universities owned PLpro inhibitors followed by efficacy testing in MA10 mice infected with
SARS-CoV-2. Molecules showing efficacy in infected mice will be advanced to human trials.


“We are delighted to be working with the University of Arizona Coronavirus research team led by
Dr. Gregory Thatcher as well as the commercialization team at Tech Launch Arizona,” said Dr.
Steve Slilaty, CEO of Sunshine Biopharma. “It is of paramount importance to find a wide array of
inhibitors for PLpro, as this virus encoded protease is responsible for the suppression of the human
immune system, thereby enabling the virus to cause severe illness,” he added.


About the University of Arizona
The University of Arizona, a land-grant university with two independently accredited medical
schools, is one of the nation’s top 50 public universities, according to U.S. News & World Report.
Established in 1885, the university is widely recognized as a student-centric university and has
been designated as a Hispanic Serving Institution by the U.S. Department of Education. The
university ranked in the top 20 in 2019 in research expenditures among all public universities,
according to the National Science Foundation, and is a leading Research 1 institution with $734
million in annual research expenditures. The university advances the frontiers of interdisciplinary
scholarship and entrepreneurial partnerships as a member of the Association of American
Universities, the 66 leading public and private research universities in the U.S. It benefits the state
with an estimated economic impact of $4.1 billion annually.


About Tech Launch Arizona
Tech Launch Arizona is the office of the University of Arizona that creates social and economic
impact through commercializing inventions stemming from university research. The office builds
connections between talented UA faculty, researchers and staff and experienced entrepreneurs
and investors, to create an ecosystem that refines ideas that start in research and innovation
and grows them into products and businesses that benefit society. TLA supports entrepreneurship
through a variety of initiatives, including training startup teams in customer discovery, providing
funding to advance early-stage inventions toward market readiness, and hosting challenges to
help students and faculty move innovative ideas from concept to societal impact. In FY2021, TLA
took in 274 invention disclosures, had 100 U.S. patents issued, and executed 124 licenses and
options for UArizona technologies. The university has launched more than 100 startups since the
office was founded in 2012.


About Sunshine Biopharma
In addition, to working on the development of a treatment for COVID-19, Sunshine Biopharma is
engaged in the development Adva-27a, a unique anticancer compound. Tests conducted to date
have demonstrated the effectiveness of Adva-27a at destroying Multidrug Resistant Cancer Cells,
including Pancreatic Cancer cells, Small-Cell Lung Cancer cells, Breast Cancer cells, and Uterine
Sarcoma cells. Clinical trials for Pancreatic Cancer indication are planned to be conducted at
McGill University’s Jewish General Hospital in Montreal, Canada. Sunshine Biopharma is the owner
of all patents and intellectual property pertaining to Adva-27a.


Safe Harbor Forward-Looking Statements
This press release may contain forward looking statements that are based on current expectations, forecasts, and
assumptions of Sunshine Biopharma, Inc. (the “Company”) that involve risks as well as uncertainties that could cause
actual outcomes and results to differ materially from those anticipated or expected. These statements appear in a
number of places in this release and include all statements that are not statements of historical fact regarding the
intent, belief or current expectations of the Company, including statements related to the Company’s drug
development activities, financial performance, and future growth. These risks and uncertainties are further described
in filings and reports by the Company with the U.S. Securities and Exchange Commission (SEC). Actual results and
the timing of certain events could differ materially from those projected in or contemplated by the forward-looking
statements due to a number of factors detailed from time to time in the Company’s filings with the SEC. Reference is
hereby made to cautionary statements and risk factors set forth in the Company’s most recent SEC filings.

Related Tag: Pharma Companies in Canada


For Additional Information:
Camille Sebaaly, CFO
Direct Line: 514-814-0464
[email protected]
www.sunshinebiopharma.com

Sunshine Biopharma, Inc. Announces Closing of $8 Million Public Offering and Uplisting to the Nasdaq Capital Market

MONTREAL, Canada, Feb. 17, 2022 (GLOBE NEWSWIRE) — Sunshine Biopharma, Inc.

(NASDAQ: “SBFM” and “SBFMW”) (the “Company” or “Sunshine Biopharma”), a pharmaceutical
company focused on the research, development and commercialization of oncology and antiviral
drugs, announced today the closing of its underwritten public offering of 1,882,353 units at a price
to the public of $4.25 per unit, for aggregate gross proceeds of $8 million, prior to deducting
underwriting discounts, commissions and other estimated offering expenses. Each unit consists of
one share of common stock, par value $0.001 per share, and two warrants, each warrant exercisable
for one share of common stock with an exercise price of $4.25.

In addition, the Company has granted Aegis Capital Corp. (“Aegis”) a 45-day option to purchase
additional shares of common pharmaceutical stock and/or warrants equal up to 15% of the number of shares and
warrants, respectively, sold in the offering solely to cover over-allotments, if any. The underwriter
partially exercised its over-allotment option with respect to 337,494 warrants to purchase shares of
common stock. At the closing, the Company issued an aggregate of 1,882,353 common shares and
4,102,200 warrants to purchase common shares.

The Company’s common stock and warrants are listed on the Nasdaq Capital under the symbols
“SBFM” and “SBFMW”, respectively.

Aegis Capital Corp. acted as sole book-running manager for the offering.
A registration statement on Form S-1 (No. 333-259394) relating to the securities being sold in this
offering was declared effective by the Securities and Exchange Commission (the “SEC”) on
February 14, 2022. The offering has been made only by means of a prospectus. Copies of the final
prospectus may be obtained on the SEC’s website, www.sec.gov, or by contacting Aegis Capital
Corp., Attention: Syndicate Department, 810 7th Avenue, 18th Floor, New York, NY 10019, by
email at [email protected], or by telephone at (212) 813-1010.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall
there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or
sale would be unlawful prior to registration or qualification under the securities laws of any such
state or jurisdiction.

About Sunshine Biopharma
Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) is the causative agent of the
ongoing COVID-19 pandemic that has claimed the lives of over 5.3 million people worldwide since
it first appeared in December 2019. There are currently no drugs that can effectively arrest
replication of the virus in people who have contracted the illness. Sunshine Biopharma has
completed the synthesis of four potential inhibitors of PLpro and subsequently identified a lead
compound, SBFM-PL4. The Company is currently advancing the development of SBFM-PL4 in
collaboration with the University of Georgia, College of Pharmacy.

In addition, to working on the development of a treatment for COVID-19, Sunshine Biopharma is
engaged in the development Adva-27a, a unique anticancer compound. Tests conducted to date
have demonstrated the effectiveness of Adva-27a at destroying Multidrug Resistant Cancer Cells,
including Pancreatic Cancer cells, Small-Cell Lung Cancer cells, Breast Cancer cells, and Uterine
Sarcoma cells. Clinical trials for Pancreatic Cancer indication are planned to be conducted at McGill
University’s Jewish General Hospital in Montreal, Canada. Sunshine Biopharma is owner of all
patents and intellectual property pertaining to Adva-27a.

Safe Harbor Forward-Looking Statements
This press release may contain forward looking statements which are based on current expectations,
forecasts, and assumptions that involve risks as well as uncertainties that could cause actual
outcomes and results to differ materially from those anticipated or expected. These statements
appear in a number of places in this release and include all statements that are not statements of
historical fact regarding the intent, belief or current expectations of the Company, including
statements related to our financial performance and future growth. These risks and uncertainties are
further defined in filings and reports by the Company with the U.S. Securities and Exchange
Commission (SEC). Actual results and the timing of certain events could differ materially from
those projected in or contemplated by the forward-looking statements due to a number of factors
detailed from time to time in our filings with the SEC. Reference is hereby made to cautionary
statements and risk factors set forth in the Company’s most recent SEC filings.

For Additional Information Contact:
Camille Sebaaly, CFO
Sunshine Biopharma Inc.
Direct Line: 514-814-0464
[email protected]
www.sunshinebiopharma.com